On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...

Bayer vice president Luiz Barberini explains how the German giant’s cooperation with suppliers fosters long-term trial ...

MediciNova has completed full patient enrolment in the COMBAT-ALS Phase IIb/III clinical trial of MN-166 (ibudilast) as a ...

Kairos Pharma has reported encouraging interim efficacy data from its Phase II study of ENV105 in individuals with mCRPC.

Belite Bio has concluded the final participant visit in its Phase III DRAGON study, which is focused on assessing the ...

Datavant has partnered with life sciences commercialisation firm Indegene to enhance recruitment of subjects for clinical ...

As China's biotech sector continues to buzz with innovation, the country is rapidly integrating into the global clinical ...

Nektar Therapeutics has presented data of its atopic dermatitis (AD) candidate rezpeg (rezpegaldesleukin), which sent the ...

The main concerns about tariffs that businesses have are higher input costs and uncertainty in long-term planning.

Amidst significant shifts in the pharmaceutical industry, the number of clinical trials has surged over the first half of ...

US pharma giant Eli Lilly has axed its Phase IIb trial of tirzepatide and bimagrumab, which was exploring the efficacy and safety of the combination in patients with obesity who have comborbid type 2 ...

In the head-to-head trial, Lilly’s oral drug emerged on top, outperforming Novo Nordisk’s semaglutide.